OncoZenge AB (publ) (STO:ONCOZ)
3.660
-0.160 (-4.19%)
Sep 4, 2026, 1:04 PM CET
OncoZenge AB Balance Sheet
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 0.75 | 3.71 | 3.86 | 12.63 | 29.14 | 51.22 |
Cash & Short-Term Investments | 0.75 | 3.71 | 3.86 | 12.63 | 29.14 | 51.22 |
Cash Growth | -51.90% | -3.86% | -69.41% | -56.67% | -43.11% | 412.23% |
Other Receivables | 2.55 | 2.54 | 0.52 | 0.64 | 0.71 | 0.85 |
Receivables | 2.55 | 2.54 | 0.52 | 0.64 | 0.71 | 0.85 |
Prepaid Expenses | 1.58 | 2.23 | 0.2 | 0.22 | 0.19 | 0.06 |
Total Current Assets | 4.88 | 8.49 | 4.58 | 13.49 | 30.04 | 52.13 |
Other Intangible Assets | 6.85 | 6.85 | 6.85 | 6.85 | 6.85 | 6.85 |
Long-Term Deferred Tax Assets | - | - | - | - | - | 3.08 |
Long-Term Deferred Charges | - | - | - | - | - | 23.17 |
Other Long-Term Assets | 15.11 | 9.06 | - | - | - | - |
Total Assets | 26.83 | 24.4 | 11.43 | 20.34 | 36.89 | 85.23 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 6.4 | 6.8 | 0.66 | 0.93 | 1.65 | 4.02 |
Accrued Expenses | 1.07 | 1.55 | 0.78 | 0.66 | 1.01 | 0.5 |
Other Current Liabilities | 2.06 | 0.07 | 0.05 | 0.11 | 0.26 | 0.39 |
Total Current Liabilities | 9.53 | 8.42 | 1.48 | 1.7 | 2.92 | 4.9 |
Long-Term Debt | 7.5 | 7.5 | - | - | - | - |
Total Liabilities | 17.03 | 15.92 | 1.48 | 1.7 | 2.92 | 4.9 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 1.56 | 1.41 | 1.3 | 1.3 | 1.3 | 1.3 |
Additional Paid-In Capital | 112.73 | 98.77 | 84.41 | 84.41 | 83.84 | 83.54 |
Retained Earnings | -104.49 | -91.7 | -75.76 | -67.07 | -51.17 | -4.52 |
Shareholders' Equity | 9.8 | 8.48 | 9.95 | 18.64 | 33.97 | 80.32 |
Total Liabilities & Equity | 26.83 | 24.4 | 11.43 | 20.34 | 36.89 | 85.23 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 7.5 | 7.5 | - | - | - | - |
Net Cash (Debt) | -6.75 | -3.79 | 3.86 | 12.63 | 29.14 | 51.22 |
Net Cash Growth | - | - | -69.41% | -56.67% | -43.11% | 412.23% |
Net Cash Per Share | -0.52 | -0.31 | 0.33 | 1.08 | 2.49 | 4.35 |
Filing Date Shares Outstanding | 14.05 | 12.65 | 11.71 | 11.71 | 11.71 | 11.71 |
Total Common Shares Outstanding | 14.05 | 12.65 | 11.71 | 11.71 | 11.71 | 11.71 |
Working Capital | -4.65 | 0.06 | 3.1 | 11.79 | 27.12 | 47.23 |
Book Value Per Share | 0.70 | 0.67 | 0.85 | 1.59 | 2.90 | 6.86 |
Tangible Book Value | 2.95 | 1.63 | 3.1 | 11.79 | 27.12 | 73.47 |
Tangible Book Value Per Share | 0.21 | 0.13 | 0.26 | 1.01 | 2.32 | 6.27 |